EN DE
Watch Camlin Fine Sciences Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Camlin Fine Sciences Limited (CAMLINFINE) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Camlin Fine Sciences Limited stock ₹27.43, price ₹79.24, that is 65.4% below the price, quality 30 out of 100. Rating: strongly overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials IN · ISIN INE052I01032

CF Camlin Fine Sciences Limited logo Thin data Nov 10, 2026

Camlin Fine Sciences Limited

CAMLINFINE · NSE
Very expensive, weak quality

Our calculation puts a fair price 65% below what the stock costs today.

Low debt
Profit last quarter +154% vs. a year ago.
Expensive Growth (revenue 5y +7.9 %/yr in INR)
Loss over the last twelve months · -0.4% net margin (TTM) · fiscal year 2026 1.6%
Fair value ₹27.43 · Strongly overvalued
Quality 30/100
Negative free cash flow
Trails peers (2/11)
Narrow moat 16/100
Thin data
⟳ Cyclical
Watch Camlin Fine Sciences Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹327.53 ₹74.15 Fair Value ₹27.43 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range ₹74.15 – ₹327.53 · fair‑value band ₹19.20 – ₹33.25 · the ₹79.24 price screens above the ₹27.43 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Camlin Fine Sciences in your weekly email

Every Wednesday you see whether Camlin Fine Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Camlin Fine Sciences Limited, together with its subsidiaries, research, develops, manufactures, and markets specialty chemicals, ingredients, and additive blend products in India and internationally.

Show moreShow less

The company offers shelf-life solutions, which include basic ingredients, such as tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), and Ascorbyl Palmitate (ASP); aroma ingredients, including vanillin and ethyl vanillin, natural vanillin, and some of its combinations; performance chemicals that include Hydroquinone (HQ), Catechol (CAT), Monomethyl Ether of HQ (MEHQ), tert butylcatechol (TBC), Guaiacol, and Veratrole; and health and wellness products comprising algae based products, such as Omega 3 fatty acids.

It sells its prodycrts under the Xtendra, Nasure, Ezential, adorr, Dinamic, and Biosus brands.

The company's products are used in food and beverage, pet food and rendering, animal nutrition, petrochemical, nutrition and health, biofuel, agrochemical, pharmaceutical, polymers, fragrance and flavor, and dyes and pigments industries.

The company was formerly known as Camlin Fine Chemicals Ltd. and changed its name to Camlin Fine Sciences Limited in August 2011. Camlin Fine Sciences Limited was founded in 1931 and is headquartered in Mumbai, India.

Stock analysis

Camlin Fine Sciences Limited (CAMLINFINE) currently trades at ₹79.24, while our model-based Fair Value estimate is ₹27.43, 65% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of ₹91.31 per share, and 2 of the 11 models we run sit above the ₹79.24 price.

Bear case: the Earnings-Based group reads lowest at ₹20.62, and 9 of the 11 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹19.20 (bear) to ₹33.25 (bull), the price of ₹79.24 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Basic Materials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Camlin Fine Sciences Limited reported revenue of ₹17.2B in FY2026 versus ₹14.0B in FY2022, a compound +5.2%/yr. Reported net income was ₹276M in FY2026, compounding −17.9%/yr from FY2022.

Key figures

Market cap ₹15.2B (≈ $162M) Micro · P/S ratio 0.80 · EPS (TTM) ₹−3.00 · Net margin 1.6% · Return on equity −9.7% · Return on assets (EBIT) 5.2% (5-year average) · Operating margin −3.6% · Revenue (TTM) ₹18.8B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 55% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −42% fair-value upside, at −65%, CAMLINFINE screens richer than that median.

Fair Value models

Bear ₹19.20 Fair Value ₹27.43 Bull ₹33.25
Price ₹79.24 · Downside -65.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings ₹52.79 ₹91.31 ₹147.36 75
Residual Income ₹28.88 ₹30.18 ₹33.25 71
EPV n/a n/a ₹0.1300 68
All 13 models by family
DCF Models
Owner Earnings ₹52.79 ₹91.31 ₹147.36 75
Earnings-Based
Graham-Dodd ₹9.78 ₹52.28 ₹72.43 63
Lynch FV ₹14.44 ₹20.62 ₹26.81 61
PEG = 1.0 ₹14.44 ₹20.62 ₹26.81 57
EPV n/a n/a ₹0.1300 68
Multiples
P/E Multiple ₹18.34 ₹24.45 ₹30.56 63
P/S Multiple ₹18.34 ₹24.45 ₹30.56 58
P/B Multiple ₹91.20 ₹121.59 ₹151.99 55
EV/EBITDA ₹6.87 ₹19.29 ₹31.71 62
Asset-Based
NCAV (Graham) ₹20.27 ₹27.16 ₹40.53 54
Economic Profit
Residual Income ₹28.88 ₹30.18 ₹33.25 71
ROIC Compounder n/a n/a ₹0.1300 68
Growth Earnings
Growth-Adj P/E ₹19.20 ₹27.43 ₹35.66 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31
How much profit the company makes from its sales and capital
Quality Growth 27
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 37
Debt, balance sheet and risk of trouble
Investment 77
Does it invest with discipline instead of growing at any price?
Low Volatility 44
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 20
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+3.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Start year 2021 (pandemic). Over 10 years: +13.4% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.9%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−17.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−17.1% vs −11.2%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 1%
Pace: the 5-year rate starts in 2021 (pandemic)

CAMLINFINE screens overvalued: fair value 65% below the price. Compare with Linde plc →

Compare Camlin Fine Sciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 753 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −65.4% · Bottom 25%
Profitability
Return on assets 1.2% · Below median
Net margin (12 months) −0.4% · Bottom 25%
Operating margin (12 months) −3.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 6.9% · Below median
Balance sheet
Debt / equity 0.29× · Above median

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/B 1.46× · Cheaper than median
P/S (12 months) 0.81× · Cheaper than median
EV/EBITDA 35.2× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 3
FUTURE (revenue growth)35 · sector 67
PAST (return on equity)0 · sector 25
HEALTH (low debt)85 · sector 95
DIVIDEND (yield)0 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wanhua Chemical Group 600309 ¥69.90 ¥68.03 −3% vs CAMLINFINE
Linde plc LIN $526.55 $446.62 −15% vs CAMLINFINE
PPG Industries, Inc PPG $124.97 $77.68 −38% vs CAMLINFINE
DSM-Firmenich AG DSFIR CHF 98.20 CHF 57.84 −41% vs CAMLINFINE
Asian Paints Limited ASIANPAINT ₹2,550 ₹1,479 −42% vs CAMLINFINE
The Sherwin-Williams Company SHW $355.76 $152.59 −57% vs CAMLINFINE
Givaudan SA GIVN CHF 4,084 CHF 1,629 −60% vs CAMLINFINE
EMS-CHEMIE HOLDING AG EMSN CHF 846.00 CHF 284.63 −66% vs CAMLINFINE
Ecolab Inc ECL $307.86 $97.18 −68% vs CAMLINFINE
Air Products and Chemicals, Inc APD $315.18 $75.33 −76% vs CAMLINFINE

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Camlin Fine Sciences Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Camlin Fine Sciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/CAMLINFINE

Frequently asked questions

Is Camlin Fine Sciences Limited (CAMLINFINE) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of ₹27.43 versus a price of ₹79.24, about 65% lower (overvalued).
What is the fair value of CAMLINFINE?
Our model-based fair value for Camlin Fine Sciences Limited is ₹27.43 (as of Nov 10, 2026), built from audited fundamentals. The current price: ₹79.24.
What is the quality score of CAMLINFINE?
Camlin Fine Sciences Limited has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Camlin Fine Sciences Limited (CAMLINFINE)?
Our model-based price target is the fair value of ₹27.43 (as of Nov 10, 2026) from 13 valuation models. Cautious scenario ₹19.20, optimistic scenario ₹33.25. It is a calculation from audited fundamentals, not an analyst target.
What is the Camlin Fine Sciences Limited stock forecast for 2026?
Our models put fair value at ₹27.43, about 65% lower versus a price of ₹79.24 (overvalued). Cautious scenario ₹19.20, optimistic scenario ₹33.25. The calculation is refreshed regularly with new filings.
What is the revenue of Camlin Fine Sciences Limited (CAMLINFINE)?
Camlin Fine Sciences Limited reported trailing-twelve-month revenue of about ₹18.8B (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Camlin Fine Sciences Limited (CAMLINFINE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Camlin Fine Sciences Limited it is ₹27.43 per share (as of Nov 10, 2026), against a price of ₹79.24. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Camlin Fine Sciences Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CAMLINFINE trades above its calculated fair value: price ₹79.24, fair value ₹27.43, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CAMLINFINE?
No. The price is what the market pays today (₹79.24); the fair value is what the company's own numbers justify (₹27.43). For Camlin Fine Sciences Limited the two are ₹51.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is Camlin Fine Sciences Limited worth?
The market values Camlin Fine Sciences Limited at about ₹15.2B (market capitalisation, as of Nov 10, 2026). Per share that is ₹79.24; our models calculate a fair value of ₹27.43 per share.
What do the bullish and bearish scenarios say about CAMLINFINE?
Our models span a range for Camlin Fine Sciences Limited: cautious scenario ₹19.20, base ₹27.43, optimistic ₹33.25 per share (as of Nov 10, 2026, price ₹79.24). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Camlin Fine Sciences Limited (CAMLINFINE)?
Balance-sheet figures for Camlin Fine Sciences Limited (as of Nov 10, 2026): return on equity −9.7%, debt of 0.29 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is CAMLINFINE from its 52-week high?
Camlin Fine Sciences Limited trades at ₹79.24, about 55% below its 52-week high of ₹177.37 and 7% above the low of ₹74.15 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of ₹27.43 is for.
Which stocks are comparable to Camlin Fine Sciences Limited?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Camlin Fine Sciences Limited stock attractive at the current price?
The data as of Nov 10, 2026: price ₹79.24, calculated fair value ₹27.43 (−65%), Quality Score 30/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CAMLINFINE calculated?
We run Camlin Fine Sciences Limited through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹27.43 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Camlin Fine Sciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Camlin Fine Sciences Limited (CAMLINFINE)?
The closing price on Nov 11, 2026 was ₹79.24. Our model-based fair value is ₹27.43, about 65% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Camlin Fine Sciences Limited right now?
The price sits above even our optimistic bull case (₹33.25). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Camlin Fine Sciences Limited

How large is the market capitalisation of Camlin Fine Sciences Limited (CAMLINFINE)?
The market capitalisation of Camlin Fine Sciences Limited is ₹15.2B (≈ $162M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Camlin Fine Sciences Limited (CAMLINFINE)?
The price-to-sales ratio of Camlin Fine Sciences Limited is 0.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Camlin Fine Sciences Limited (CAMLINFINE)?
Earnings per share at Camlin Fine Sciences Limited are ₹−3.00. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Camlin Fine Sciences Limited (CAMLINFINE)?
The net margin of Camlin Fine Sciences Limited is 1.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Camlin Fine Sciences Limited (CAMLINFINE)?
The return on equity (ROE) of Camlin Fine Sciences Limited is −9.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Camlin Fine Sciences Limited (CAMLINFINE)?
On an EBIT basis the return on assets of Camlin Fine Sciences Limited is 5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Camlin Fine Sciences Limited (CAMLINFINE)?
The operating margin of Camlin Fine Sciences Limited is −3.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Camlin Fine Sciences Limited (CAMLINFINE)?
Revenue at Camlin Fine Sciences Limited is growing +6.9% versus a year earlier (3y avg +0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Camlin Fine Sciences Limited (CAMLINFINE)?
Earnings per share at Camlin Fine Sciences Limited are growing +154% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Camlin Fine Sciences Limited (CAMLINFINE) generate?
The free cash flow of Camlin Fine Sciences Limited is −₹331M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Camlin Fine Sciences Limited (CAMLINFINE) carry?
The net debt of Camlin Fine Sciences Limited is ₹5.8B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Camlin Fine Sciences Limited in the live analysis

One click puts Camlin Fine Sciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.